1. Ferlay J, Shin HR, Bray F, et al.: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–917.
2. Jarnagin WR, Gonen M, Fong Y, et al.: Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002; 236: 397–406.
3. Poon RT, Fan ST, Lo CM, et al.: Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg 2004; 240: 698–708.
4. Marcucci C, Madjdpour C and Spahn DR: Allogeneic blood transfusions: benefit, risks and clinical indications in countries with a low or high human development index. British medical bulletin 2004; 70: 15–28.
5. Tomimaru Y, Wada H, Marubashi S, et al.: Fresh frozen plasma transfusion does not affect outcomes following hepatic resection for hepatocellular carcinoma. World J Gastroenterol 2010; 16: 5603–10.
6. Harada N, Shirabe K, Maeda T, et al.: Blood transfusion is associated with recurrence of hepatocellular carcinoma after hepatectomy in Child–Pugh class A patients. World J Surg 2015; 39: 1044–51.
7. Wada H, Eguchi H, Nagano H, et al.: Perioperative allogenic blood transfusion is a poor prognostic factor after hepatocellular carcinoma surgery: a multi-center analysis. Surg Today 2018; 48: 73–79.
8. Kuroda S, Tashiro H, Kobayashi T, et al.: No impact of perioperative blood transfusion on recurrence of hepatocellular carcinoma after hepatectomy. World J Surg 2012; 36: 651–8.
9. Yang T, Lu J-H, Lau WY, et al.: Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma: A Propensity Score Matching Analysis. J Hepatol 2016; 64: 583–93.
10. Honmyo N, Kobayashi T, Hamaoka M, et al.: Comparison of new prognostic systems for patients with resectable hepatocellular carcinoma: albumin‐bilirubin grade and albumin‐indocyanine green evaluation grade. Hepatol Res, 2019.
11. Horino K, Beppu T, Kuroki H, et al.: Glasgow Prognostic Score as a useful prognostic factor after hepatectomy for hepatocellular carcinoma. Int J Clin Oncol 2013; 18: 829–38.
12. Harimoto N, Yoshizumi T, Shimagaki T, et al.: Inflammation-based prognostic score in patients with living donor liver transplantation for hepatocellular carcinoma. Anticancer Res 2016; 36: 5537–542.
13. Abe T, Tashiro H, Kobayashi T, et al.: Glasgow prognostic score and prognosis after hepatectomy for hepatocellular carcinoma. World J Surg 2017; 41: 1860–70.
14. Abe T, Amano H, Kobayashi T, et al.: Preoperative neutrophil-to-lymphocyte ratio as a prognosticator in early stage pancreatic ductal adenocarcinoma. Eur J Surg Oncol 2018; 44: 1573–9.
15. Voron T, Tselikas L, Pietrasz D, et al.: Sarcopenia impacts on short-and long-term results of hepatectomy for hepatocellular carcinoma. Ann Surg 2015; 261: 1173–83.
6. Kamachi S, Mizuta T, Otsuka T, et al.: Sarcopenia is a risk factor for the recurrence of hepatocellular carcinoma after curative treatment. Hepat Res 2016; 46: 201–8.
17. Harimoto N, Shirabe K, Yamashita YI, et al.: Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg 2013; 100: 1523-30.
18. Hao S, Fan P, Chen S, et al.: Distinct recurrence risk factors for intrahepatic metastasis and multicenter occurrence after surgery in patients with hepatocellular carcinoma. J Gastrointest Surg 2017; 21: 312–20.
19. Kim JM, Kwon C, Joh J-W, et al.: Intrahepatic metastasis is more risky than multiple occurrence in hepatocellular carcinoma patients after curative liver resection. Hepato-gastroenterology 2015; 62: 399–404.
20. Tsai T-J, Chau G-Y, Lui W-Y, et al.: Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 2000; 127: 603-8.
21. Esnaola NF, Lauwers GY, Mirza NQ, et al. Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg 2002; 6: 224–32.
22. Mitsiopoulos N, Baumgartner R, Heymsfield S, et al.: Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 1998; 85: 115–22.
23. Dodson RM, Firoozmand A, Hyder O, et al.: Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies. J Gastrointest Surg 2013; 17: 2123–32.
24. Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age and ageing 2010; 39: 412-23
25. Cruz-Jentoft AJ, Landi F, Schneider SM, et al.: Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age and Ageing 2014; 43: 748–59.
26. Valenzuela T: Efficacy of progressive resistance training interventions in older
adults in nursing homes: a systematic review. J Am Med Dir Assoc 2012; 13: 418–4128.
27. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a
secretory organ. Nat Rev Endocrinol 2012; 8: 457.
28. Tessari P. Protein metabolism in liver cirrhosis: from albumin to muscle
myofibrils. Curr Opin Clin Nutr Metab Care 2003; 6: 79-85.
29. Dasarathy S. Consilience in sarcopenia of cirrhosis. J Cachexia Sarcopenia
Muscle 2012; 3: 225-37.
30. Kaido T, Ogawa K, Fujimoto Y et al. Impact of sarcopenia on survival in patients
undergoing living donor liver transplantation. Am J of Transplant 2013; 13: 1549-56.
31. Asahara T, Katayama K, Itamoto T, et al.: Perioperative blood transfusion as a prognostic indicator in patients with hepatocellular carcinoma. World J Surg 1999; 23: 676–80.
32. Vamvakas EC and Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 2001; 97: 1180–95.
33. Sugita S, Sasaki A, Iwaki K et al. Prognosis and postoperative lymphocyte count
in patients with hepatocellular carcinoma who received intraoperative allogenic blood
transfusion: a retrospective study. Eur J Surg Oncol (EJSO) 2008; 34: 339-45.
34. Kwon AH, Matsui Y, Kamiyama Y. Perioperative blood transfusion in
hepatocellular carcinomas: influence of immunologic profile and recurrence free
survival. Cancer 2001; 91: 771-8.
35. Itasaka H, Yamamoto K, Taketomi A et al. Influence of blood transfusion on
postoperative long-term liver function in patients with hepatocellular carcinoma.
Hepatogastroenterology 1995; 42: 465-8.
36. Lopez-Aguiar AG, Ethun CG, Pawlik TM, et al. Association of perioperative transfusion with recurrence and survival after resection of distal cholangiocarcinoma: A 10-institution study from the US extrahepatic biliary malignancy consortium. Ann Surg Oncol 2019; 26:1814–23.
37. Park HM, Park SJ, Shim JR, et al. Perioperative transfusion in pancreatoduodenectomy: The double-edged sword of pancreatic surgeons. Medicine (Baltimore) 2017; 96: e9019.